RE:RE:RE:Impact of Ryplazmin Approval
Ha ! thats a great question ! I am putting myself out there enough without pretending to know exactly when !
What I will say is that I know definitively that the Board sub committee have been seriously engaged in the process with SR management for at least the last six months. The 4050 FDA IND approval and Allstrom data were MAJOR cogs in the process in terms of risk reduction for prospective partners. BoD and Sr management met in NY in early Sept to hear engagement pitches from a handful of Tier one Investment banks to discuss Voucher options, IP Monetization and Nasdaq listing.
My sense is there are very significant discussions going on right now with the partners we hope would be engaged. What that means in terms of translation into an actual CASH DEAL is anyone's guess. I would doubt its a Q4 thing, more likely Q1 best case. But that aint that far off.... There are certainly alot of things lining up to suggest this might finally be the time. Even without a deal in that time frame, getting a first drug with huge potential to market in Q1 aint that bad either.
I maintain, this company has become MUCH more fundable with the recent developments at this valuation, and I dont think enough people have their head around that reality.
It just goes to show how powerful the effects are of repeatedly disappointing and overpromising in the past.... Its not an easy ship to turn around.